Partners

A true partner from discovery to commercialization

AVS Bio is a global company supporting the development of biologics for animal and human health with products and services at its operational sites in North America and Europe. The company has decades of experience in specific pathogen free technologies, novel (therapeutic) antibody discovery and optimisation, and protein production leveraging its industry-leading in vivo, in vitro and in silico technologies and deep scientific expertise. AVS Bio partners with biologics developers across a broad range of animal and human health indications, supporting programs from early discovery through preclinical development.

AVS Bio offers design-driven antibody discovery and development services, tailored to target insights and lead antibody requirements.  Since 2018, AVS Bio has supported more than 100 life sciences companies launch successful lead antibody programs, including the development of 10 antibodies that entered clinical trials. This includes more than 300 projects ranging from targeted tool generation to comprehensive antibody discovery and development, with end-to-end support from idea to production for preclinical testing. AVS Bio completed over 3,250 standalone protein production and purification programs over the past decades. Our clients trust us for our expertise, efficiency, and commitment to turning complex challenges into successful outcomes.
 

For more information, visit https://www.avsbio.com/ 

Make the Most of our Expertise in Tissue Based Biomarker Analysis

HistologiX is a trusted GLP & GCP compliant CRO, specialising in advanced, tissue-based biomarker analysis across therapeutic and medical device development pipelines. Known for their scientific rigor and consultative approach, HistologiX supports both clinical and pre-clinical studies with a comprehensive suite of histology, immunohistochemistry (IHC), immunofluorescence (IF), in situ hybridization (ISH), and cutting-edge digital image analysis services.

HistologiX's proactive and flexible approach accommodates novel targets as well as those already well defined. They offer an extensive panel of chromogenic and immunofluorescence, single and multiplex IHC assays, all with outstanding reproducibility. Drawing on the expertise of their scientific team HistologiX develops, optimises and validates biomarker assays for use in distribution, proof of concept of mechanism of action studies. For each project, their experienced scientists work as an extension of your in-house team to define your bespoke project requirements and customise the study plan to ensure you get the results you need. They provide an excellent quality technical service supporting biomarker evaluation of cutting-edge therapeutics including cell and gene therapies, oncolytic viruses, therapeutic antibodies, small molecules, and RNA modifying enzymes. 

Partner with HistologiX to generate and turn tissue-based data into decisions to accelerate the development of your therapeutic or medical device.

For more information, visit www.histologix.com

A leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry.

Scendea are committed problem solvers, redefining the meaning of customer service, with a focus on reducing time-to-market and minimising development costs. 

Scendea was founded as a result of a management buyout of the product development and regulatory consulting function of a clinical research organisation. Their origin dates back over 20 years, with involvement in over 1,000 development programmes. Their international team offers strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory, which guide products efficiently from early development to marketing approval. 

Their scientific excellence, industry experience, commercial awareness and a collaborative approach allow their expert team to solve complex issues associated with medicinal product development. Scendea has team members based in the UK, Ireland, the Netherlands and the US, who deliver innovative and high-quality solutions aligned to jurisdiction-specific regulatory requirements. 

At Scendea they collaborate, innovate, and together with their clients, they succeed. You can visit www.scendea.com to learn more.

A leading service provider for recombinant antibody expression in CHO cells.

Evitria is an established, global antibody expression service provider located in Zurich, Switzerland. They are specialised in CHO-based transient expression of antibodies (including bispecific and fusion antibodies) and other proteins. 

With a track record of more than 125,000 transfections performed and more than 20,000 antibodies / antibody based molecules expressed and purified for clients from the Americas, Europe, Asia and Australia – ranging from academic laboratories and small biotech start-ups to global biopharmaceutical companies – you can benefit from Evitria’s expertise when looking to entrust a partner with your complete antibody production or to manage capacity bottlenecks with single projects.

A leading developer of best-in-class lab-on-chip screening platforms for a variety of 3D diseases.

ScreenIn3D is dedicated to revolutionising drug discovery through patented lab-on-a-chip technology that provides higher throughput investigation of candidate molecules on translational live tissue samples and complex 3D models of biology. This can reduce the uncertainty associated with existing preclinical models.

The company pioneers a screening technology tailored for biotechs and drug developers in oncology and immune-oncology, offering bespoke solutions. Amidst considerable uncertainty surrounding molecule efficacy, our platform delivers intricate, scalable assays generating over 20 times more data than existing methods, by upscaling screening of tissue-derived, predictive human models of disease.

This breakthrough empowers the industry to precisely assess molecule efficacy, enhancing candidate selection, producing better data, faster, more economically and with less failures. Learn more.